OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Giulietta Maruggi, Cuiling Zhang, Junwei Li, et al.
Molecular Therapy (2019) Vol. 27, Iss. 4, pp. 757-772
Open Access | Times Cited: 416
Giulietta Maruggi, Cuiling Zhang, Junwei Li, et al.
Molecular Therapy (2019) Vol. 27, Iss. 4, pp. 757-772
Open Access | Times Cited: 416
Showing 1-25 of 416 citing articles:
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
Eakachai Prompetchara, Chutitorn Ketloy, Tanapat Palaga
Asian Pacific Journal of Allergy and Immunology (2020)
Open Access | Times Cited: 1569
Eakachai Prompetchara, Chutitorn Ketloy, Tanapat Palaga
Asian Pacific Journal of Allergy and Immunology (2020)
Open Access | Times Cited: 1569
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Uǧur Şahin, Alexander Muik, Isabel Vogler, et al.
Nature (2021) Vol. 595, Iss. 7868, pp. 572-577
Open Access | Times Cited: 715
Uǧur Şahin, Alexander Muik, Isabel Vogler, et al.
Nature (2021) Vol. 595, Iss. 7868, pp. 572-577
Open Access | Times Cited: 715
A Thermostable mRNA Vaccine against COVID-19
Na-Na Zhang, Xiao-Feng Li, Yong‐Qiang Deng, et al.
Cell (2020) Vol. 182, Iss. 5, pp. 1271-1283.e16
Open Access | Times Cited: 616
Na-Na Zhang, Xiao-Feng Li, Yong‐Qiang Deng, et al.
Cell (2020) Vol. 182, Iss. 5, pp. 1271-1283.e16
Open Access | Times Cited: 616
The clinical progress of mRNA vaccines and immunotherapies
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 492
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 492
Nanomaterial Delivery Systems for mRNA Vaccines
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 458
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 458
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Abishek Wadhwa, Anas Aljabbari, Abhijeet Lokras, et al.
Pharmaceutics (2020) Vol. 12, Iss. 2, pp. 102-102
Open Access | Times Cited: 454
Abishek Wadhwa, Anas Aljabbari, Abhijeet Lokras, et al.
Pharmaceutics (2020) Vol. 12, Iss. 2, pp. 102-102
Open Access | Times Cited: 454
The promise of mRNA vaccines: a biotech and industrial perspective
Nicholas A. C. Jackson, Kent E. Kester, Danilo R. Casimiro, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 428
Nicholas A. C. Jackson, Kent E. Kester, Danilo R. Casimiro, et al.
npj Vaccines (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 428
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 414
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 414
Nanodelivery of nucleic acids
Bárbara B. Mendes, João Conniot, Aviram Avital, et al.
Nature Reviews Methods Primers (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 388
Bárbara B. Mendes, João Conniot, Aviram Avital, et al.
Nature Reviews Methods Primers (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 388
Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review
Esteban Ortiz‐Prado, Katherine Simbaña‐Rivera, Lenin Gómez‐Barreno, et al.
Diagnostic Microbiology and Infectious Disease (2020) Vol. 98, Iss. 1, pp. 115094-115094
Open Access | Times Cited: 370
Esteban Ortiz‐Prado, Katherine Simbaña‐Rivera, Lenin Gómez‐Barreno, et al.
Diagnostic Microbiology and Infectious Disease (2020) Vol. 98, Iss. 1, pp. 115094-115094
Open Access | Times Cited: 370
mRNA vaccines manufacturing: Challenges and bottlenecks
Sara Sousa Rosa, D.M.F. Prazeres, Ana M. Azevedo, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2190-2200
Open Access | Times Cited: 369
Sara Sousa Rosa, D.M.F. Prazeres, Ana M. Azevedo, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2190-2200
Open Access | Times Cited: 369
Self-amplifying RNA vaccines for infectious diseases
Kristie Bloom, Fiona T. van den Berg, Patrick Arbuthnot
Gene Therapy (2020) Vol. 28, Iss. 3-4, pp. 117-129
Open Access | Times Cited: 343
Kristie Bloom, Fiona T. van den Berg, Patrick Arbuthnot
Gene Therapy (2020) Vol. 28, Iss. 3-4, pp. 117-129
Open Access | Times Cited: 343
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
Daniela Călina, Anca Oana Docea, Demetrios Petrakis, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 1, pp. 3-16
Open Access | Times Cited: 318
Daniela Călina, Anca Oana Docea, Demetrios Petrakis, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 1, pp. 3-16
Open Access | Times Cited: 318
Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
Min Qiu, Yan Tang, Jinjin Chen, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 8
Open Access | Times Cited: 315
Min Qiu, Yan Tang, Jinjin Chen, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 8
Open Access | Times Cited: 315
The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 312
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 312
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Sergio Linares-Fernández, Céline Lacroix, Jean‐Yves Exposito, et al.
Trends in Molecular Medicine (2019) Vol. 26, Iss. 3, pp. 311-323
Open Access | Times Cited: 290
Sergio Linares-Fernández, Céline Lacroix, Jean‐Yves Exposito, et al.
Trends in Molecular Medicine (2019) Vol. 26, Iss. 3, pp. 311-323
Open Access | Times Cited: 290
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
Shuqin Xu, Kunpeng Yang, Rose Li, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6582-6582
Open Access | Times Cited: 280
Shuqin Xu, Kunpeng Yang, Rose Li, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6582-6582
Open Access | Times Cited: 280
Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 225
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 225
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Emily H. Pilkington, Estelle J. A. Suys, Natalie L. Trevaskis, et al.
Acta Biomaterialia (2021) Vol. 131, pp. 16-40
Open Access | Times Cited: 204
Emily H. Pilkington, Estelle J. A. Suys, Natalie L. Trevaskis, et al.
Acta Biomaterialia (2021) Vol. 131, pp. 16-40
Open Access | Times Cited: 204
COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 200
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 200
An Update on Self-Amplifying mRNA Vaccine Development
Anna K. Blakney, Shell Ip, Andrew J. Geall
Vaccines (2021) Vol. 9, Iss. 2, pp. 97-97
Open Access | Times Cited: 196
Anna K. Blakney, Shell Ip, Andrew J. Geall
Vaccines (2021) Vol. 9, Iss. 2, pp. 97-97
Open Access | Times Cited: 196
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
Itziar Gómez-Aguado, Julen Rodríguez-Castejón, Mónica Vicente-Pascual, et al.
Nanomaterials (2020) Vol. 10, Iss. 2, pp. 364-364
Open Access | Times Cited: 188
Itziar Gómez-Aguado, Julen Rodríguez-Castejón, Mónica Vicente-Pascual, et al.
Nanomaterials (2020) Vol. 10, Iss. 2, pp. 364-364
Open Access | Times Cited: 188
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
Basmah N. Aldosari, Iman M. Alfagih, Alanood S. Almurshedi
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 206-206
Open Access | Times Cited: 180
Basmah N. Aldosari, Iman M. Alfagih, Alanood S. Almurshedi
Pharmaceutics (2021) Vol. 13, Iss. 2, pp. 206-206
Open Access | Times Cited: 180
Formulation and Delivery Technologies for mRNA Vaccines
Chunxi Zeng, Chengxiang Zhang, Patrick Walker, et al.
Current topics in microbiology and immunology (2020), pp. 71-110
Open Access | Times Cited: 179
Chunxi Zeng, Chengxiang Zhang, Patrick Walker, et al.
Current topics in microbiology and immunology (2020), pp. 71-110
Open Access | Times Cited: 179
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
Jonaid Ahmad Malik, Sakeel Ahmed, Mir Aroosa, et al.
Journal of Infection and Public Health (2022) Vol. 15, Iss. 2, pp. 228-240
Open Access | Times Cited: 179
Jonaid Ahmad Malik, Sakeel Ahmed, Mir Aroosa, et al.
Journal of Infection and Public Health (2022) Vol. 15, Iss. 2, pp. 228-240
Open Access | Times Cited: 179
